ACSL4 and breast carcinoma: In turn, sensitivity to rosiglitazone could be explained by the fact that MDA-MB-231 breast cancer cells express very high levels of ACSL4 and, as shown in the results above, ACSL4 affects the up and downregulators of mTOR and regulates mTORC1 and mTORC2 activities.